文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

多替拉韦/拉米夫定在未治疗HIV感染者中的长期有效性与耐受性:多中心队列96周分析

Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

96周时DTG/3TC组病毒抑制率94.0%,CD4平均增加295.5 cells/μL(95%CI 269.9-321.1),总体停药9.8%、因不良事件停药1.3%。多因素分析显示DTG/3TC与其他方案在病毒抑制和CD4增加上无显著差异,但其他方案停药风险更高。

要点

  • DTG/3TC组96周病毒抑制率94.0%,CD4平均增加295.5 cells/μL(95%CI 269.9-321.1)。
  • DTG/3TC组96周内总体停药9.8%,因不良事件停药1.3%。
  • 多因素分析中DTG/3TC与其他一线方案病毒抑制及CD4增加无显著差异,但其他方案停药风险更高。

核心结论

  • 在这个大型多中心队列的初治HIV感染者中,DTG/3TC在96周时与最常用一线方案有效性相似,且持续性和耐受性更好。

主要发现

  • 2359例中DTG/3TC使用472例(20.0%),比克替拉韦/替诺福韦艾拉酚胺/恩曲他滨1134例(48.1%),DTG+替诺福韦二吡呋酯/恩曲他滨300例(12.7%),DTG/阿巴卡韦/拉米夫定273例(11.6%),达芦那韦/考比司他/替诺福韦艾拉酚胺/恩曲他滨180例(7.6%)。
  • DTG/3TC起始者96周时94.0%达到病毒抑制,CD4平均增加295.5 cells/μL(95%CI 269.9-321.1)。
  • DTG/3TC起始后96周内总体停药9.8%,因不良事件停药1.3%。
  • 多因素分析中DTG/3TC与其他方案在病毒抑制或CD4增加上无显著差异。
  • 以非DTG/3TC方案起始ART与总体停药及因不良事件停药风险更高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV from CoRIS, a multicentre cohort in Spain, in 2018-23. METHODS: We used multivariable regression models to compare viral suppression (VS) (HIV RNA viral load <50 copies/mL), change in CD4 cell counts, persistence and treatment discontinuations due to adverse events (AEs), at 96 (±24) weeks after treatment initiation. RESULTS: Of 2359 participants, DTG/3TC was prescribed in 472 (20.0%), bictegravir/tenofovir alafenamide (TAF)/emtricitabine (FTC) in 1134 (48.1%), DTG + tenofovir disoproxil fumarate/FTC in 300 (12.7%), DTG/abacavir/3TC in 273 (11.6%) and darunavir/cobicistat/TAF/FTC in 180 (7.6%). At 96 weeks from treatment initiation, 94.0% of participants initiating with DTG/3TC achieved VS, and the mean increase in CD4 cell counts was 295.5 cells/μL (95% CI: 269.9-321.1). During the first 96 weeks after DTG/3TC initiation, 9.8% and 1.3% discontinued their initial regimen, overall and due to AEs, respectively. In multivariable analyses, we did not find significant differences in VS or increase in CD4 cell counts among participants initiating with DTG/3TC compared with other regimens. Initiating ART with a regimen other than DTG/3TC was associated with a higher risk of treatment discontinuation, overall and due to AEs. CONCLUSIONS: Among treatment-naive people with HIV from this large multicentre cohort, DTG/3TC had similar effectiveness and better persistence and tolerability than those of the most frequently prescribed first-line regimens at 96 weeks.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Suárez-García I, Alejos B, Moreno C, et al. Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks. J Antimicrob Chemother. 2025. PMID: 39710424. doi:10.1093/jac/dkae456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。